A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

which relies on the process of endocytosis. By designing drugs to use the CD36 pathway, researchers were able to deliver 7.7 to 22.3 times more of the drug inside cancerous cells. This change ...

This new process for endocytic drugs represents a ... are additional cell receptors that could be targeted for chemical endocytosis, which Li's laboratory continues to explore.

This new process for endocytic drugs represents a ... are additional cell receptors that could be targeted for chemical endocytosis, which his laboratory continues to explore.

Current anticancer treatments essentially target the primary tumor cells that proliferate quickly, but do not effectively ...

The strategy called chemical endocytic medicinal chemistry (CEMC) takes advantage of a natural process where cells "swallow" molecules called endocytosis. It could change the future of drug design ...

Rule-breaking drug design takes advantage of CD36-dependent pathway A research team of scientists from Duke University School ...

This new process for endocytic drugs represents a paradigm shift ... it is likely that there are additional cell receptors that could be targeted for chemical endocytosis, which his laboratory ...

Current anticancer treatments essentially target the primary tumour cells that proliferate quickly, but do not effectively ...

The strategy called chemical endocytic medicinal chemistry (CEMC) takes advantage of a natural process where cells "swallow" molecules called endocytosis. It could change the future of drug design ...